For a heart just damaged by a blocked artery, timing matters. So does access. That is what makes a new experimental treatment ...

The skin over a mouse’s shoulders warmed up after a dozen days on tirzepatide. That heat map, taken with an infrared camera, pointed to a familiar patch of tissue between the shoulder blades: brown ...

Good afternoon, and welcome to Niagen Bioscience Inc.'s 2025 results investor call. With us today are Niagen Bioscience Inc.'s Chief Executive Officer, Rob Fried; Chief Financial Officer, Ozan Pamir; ...

Niagen Bioscience Inc (NASDAQ:NAGE) Q4 2025 Earnings Call Transcript March 4, 2026 Niagen Bioscience Inc beats earnings expectations. Reported EPS is $0.05, expectations were $0.02. Operator: Ladies ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery comp ...

Roche has decided to stop developing satralizumab for bone health in Duchenne muscular dystrophy, the company announced.

This study presents a valuable finding on the mutational order for common alterations in colorectal cancer. The evidence of in vitro growth assays comparing mutations is solid, although inclusion of ...

EAE-induced neuroinflammation. Using immuohistochemistry, flow cytometry, and single-cell RNAseq of doublets to interrogate cell-cell interactions, the authors provide solid evidence that macrophages, ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a ...

Scientists at Stanford Medicine have discovered a treatment that can reverse cartilage loss in aging joints and even prevent arthritis after knee injuries. By blocking a protein linked to aging, the ...

ORLANDO, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Wesley Pharmaceuticals, a state-of-the-art 503B outsourcing facility, and sister brand of the nation’s leading 503A and 503B compounding pharmacy, ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.